NCT00428142 - Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

January 6, 2012

Conditions

Lymphoma

Interventions

BIOLOGICAL

rituximab

375mg/m2 day 1

DRUG

bortezomib

1.3mg/m2 days 1 \& 8

DRUG

cyclophosphamide

750mg/m2 day 1

DRUG

prednisone

40mg/m2 days 1-5

DRUG

vincristine sulfate

1.4mg/m2 day 1 (dose capped at 2mg)

Trial Locations (19)

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

V8R 6V5

BCCA - Vancouver Island Cancer Centre, Victoria

R3E 0V9

CancerCare Manitoba, Winnipeg

E1C 6Z8

The Moncton Hospital, Moncton

B3H 1V7

QEII Health Sciences Center, Halifax

P3E 5J1

Regional Cancer Program of the Hopital Regional, Greater Sudbury

N6A 4L6

London Regional Cancer Program, London

L5M 2N1

Credit Valley Hospital, Mississauga

P7B 6V4

Thunder Bay Regional Health Science Centre, Thunder Bay

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

M9N 1N8

Humber River Regional Hospital, Toronto

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

H2W 1S6

McGill University - Dept. Oncology, Montreal

G1S 4L8

CHA-Hopital Du St-Sacrement, Québec

S4T 7T1

Allan Blair Cancer Centre, Regina